Dr. Sezar and Dr. Stratigos discuss the FDA approvals of cemiplimab-rwlc in advanced non–small cell lung cancer and advanced basal cell carcinoma.

Dr. Abramson discusses the significance of the FDA approval of liso-cel in refractory large B-cell lymphoma and provided insight into the efficacy and safety profiles of the CAR T-cell therapy as reported in the TRANSCEND NHL 001 trial.

In our exclusive interview, Riedel and Van Tine discussed the multidisciplinary management of patients with sarcoma, the clinical impact of the FDA approval of ripretinib in the gastrointestinal stromal tumor paradigm, and other exciting advances in sarcoma.

Riad Salem, MD, discusses the unique elements of the radioembolization technology, the data that supported the regulatory approval, and the anticipated future for TheraSphere in HCC.

Dr. Pagel discusses the advances that have been made with PI3K inhibitors in lymphoid malignancies, the impact of the FDA approval of umbralisib on the treatment paradigm in follicular lymphoma and marginal zone lymphoma, and ongoing research poised to expand the armamentarium.

Dr. Saba shared the ins and outs of nasopharyngeal carcinoma, ongoing clinical trials, and the complexities of managing the rare disease.

Dr. Sonpavde discusses key data presented during the 2021 Genitourinary Cancers Symposium in urothelial carcinoma and anticipated research directions with immunotherapy, chemotherapy, and antibody-drug conjugates.

In our exclusive interview, Fowler discussed the data that served as the basis for the accelerated approval of umbralisib in marginal zone lymphoma and follicular lymphoma, explained the implications of the regulatory decision on clinical practice, and detailed potential next steps for the PI3Kδ and CK1ε inhibitor.

In our exclusive interview, Weiss discussed the significance of the FDA approval of trilaciclib in extensive-stage small cell lung cancer and key efficacy and safety data that have been reported with the CDK4/6 inhibitor.

In our exclusive interview, Dr. Choueiri and Dr. Motzer discuss the clinical implications of the phase 3 CheckMate-9ER trial in advanced renal cell carcinoma and how to best use the combination in practice.